A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- ‘I want to be there for it’: Area’s first cancer survivorship clinic treating patientson October 14, 2019 at 7:52 pm
She started chemotherapy and radiation treatments before having surgery. Two scans later, there’s no sign of cancer. “Scan is clear,” Jokinen said. “So, I get to be a survivor.” But, Jokinen says one ...
- NCI awards $1.87 million grant to help patients navigate costs of cancer careon October 14, 2019 at 7:51 pm
Our intervention addresses the financial difficulties that so many cancer patients face: How do you afford cancer treatment? How do you make sense of your insurance and understand your out-of-pocket ...
- Medline Awards Nonprofit Organizations Grants to Tackle Breast Cancer-Related Issueson October 14, 2019 at 7:39 pm
Oct. 14, 2019 /PRNewswire/ -- Medline and the Medline Foundation today awarded eight nonprofit organizations with grants to increase awareness, early detection, prevention and/or treatment of breast ...
- ‘Cooling Cap’ Lets Some Cancer Patients Keep Their Hair While Going Through Chemotherapyon October 14, 2019 at 6:21 pm
BALTIMORE (WJZ) — A new device may allow some cancer patients to keep their hair during chemotherapy treatment. The device, called a cooling cap, fits over a patient’s head and protects their hair ...
- I Spent 10 Years Keeping My Breast Cancer a Secret from My Sonon October 14, 2019 at 5:35 pm
Decision done: We weren’t going to tell him. I found out in January that the cancer wasn’t growing, so they wanted to watch and wait four months. Through radiation treatment I became really tired, but ...
- I Survived Cancer Once—Then I Was Diagnosed Againon October 14, 2019 at 5:34 pm
A year later I was diagnosed with papillary thyroid cancer after my doctor found a small nodule in my neck during a routine visit for a sore throat. I endured several years of tests and treatments ...
- NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatmentson October 14, 2019 at 12:27 pm
The company is developing a diverse portfolio of new cancer treatments that aim to perfect the process of T-cell activation and direction in the body. Tmunity has 14 therapies in its pipeline in ...
- Children’s, UC Health hit milestone in 1-second cancer treatmenton October 14, 2019 at 9:29 am
has been researching the value of such ultra-high-dose-rate proton treatment with the Cincinnati Children’s/UC Health Proton Therapy ... an international group researching the use of high doses of ...
- Cancer Data Provides Insights into Treatment, Diagnosis Trendson October 14, 2019 at 6:34 am
Researchers outlined mortality and incident trends for each selected cancer and characterized the resulting “signatures.” For some cancers, such as Hodgkin’s lymphoma and chronic myeloid leukemia (CML ...
via Bing News